A novel formulation of the prostate cancer drug abiraterone acetate - currently marketed as Zytiga - will dramatically improve the quality of life for people suffering from prostate cancer, as pre-clinical trials show the new formulation improves the drug's effectiveness by 40 per cent.
from Health & Medicine News -- ScienceDaily https://www.sciencedaily.com/releases/2020/06/200620141948.htm
No comments:
Post a Comment